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Mice that are deficient in suppressor of cytokine signaling–1 (SOCS-1) succumb to neonatal 
mortality that is associated with extensive cellular infiltration of many tissues. T cells seem 
to be necessary for disease, which can be alleviated largely by neutralizing interferon-
 
 
 
. 
Examining T cell receptor (TCR) specificity shows that even monospecific T cells can mediate 
disease in SOCS-1–deficient mice, although disease onset is substantially faster with a 
polyclonal T cell repertoire. A major phenotype of SOCS-1
 
 
 
/
 
 
 
 mice is the accumulation of 
CD44
 
high
 
CD8
 
 
 
 peripheral T cells. We show that SOCS-1–deficient CD8, but not CD4, T cells 
proliferate when transferred into normal (T cell–sufficient) mice, and that this is dependent 
on two signals: interleukin (IL)-15 and self-ligands that are usually only capable of stimulating 
homeostatic expansion in T cell–deficient mice. Our findings reveal that SOCS-1 normally 
down-regulates the capacity of IL-15 to drive activation and proliferation of naive CD8 
T cells receiving TCR survival signals from self-ligands. We show that such dysregulated 
proliferation impairs the deletion of a highly autoreactive subset of CD8 T cells, and increases 
their potential for autoimmunity. Therefore, impaired deletion of highly autoreactive CD8 
T cells, together with uncontrolled activation of naive CD8 T cells by homeostatic survival 
ligands, may provide a basis for the T cell–mediated disease of SOCS-1
 
 
 
/
 
 
 
 mice.
 
Suppressor of cytokine signaling–1 (SOCS-1)
is a negative feedback regulator of cytokine
signaling (1–3) that acts on JAKs by directly
binding to, and inhibiting, their tyrosine-ki-
nase activity (4) and by facilitating ubiquitina-
tion, which targets these kinases for proteoso-
mal degradation (5, 6). SOCS-1 expression is
induced in vitro by many cytokines, including
IL-2, -4, -6, -7, -9, -10, -13, and -15; TNF
 
 
 
;
types I and II IFN, as well as by several col-
ony-stimulating factors, growth factors, and hor-
mones (7–10). Its ability to inhibit the activity of
several of these cytokines and other factors in
vitro also was reported (7–9, 11).
To better understand the role of SOCS-1
in vivo, various SOCS-1–deficient mice have
been generated (12–14). Mice with targeted
disruption of SOCS-1 throughout the whole
animal show extensive pathology that leads to
mortality by 3 wk of age (12, 14). Disease con-
sists of lymphocytopenia, growth retardation,
fatty liver degeneration, and severe inflammation
in multiple organs. A major underlying cause
of this disease seems to be dysregulated IFN-
 
 
 
signaling, because SOCS-1–deficient mice that
are crossed to IFN-
 
 
 
 
 
/
 
 
 
 mice survive as neonates
and appear relatively healthy up to 
 
 
 
6 mo of
age (15–17). After this time, double-deficient
mice begin to show susceptibility to IFN-
 
 
 
–
independent disease, with evidence of polycystic
kidneys and inflammation (18). This indicates
that pathology is not driven entirely by IFN-
 
 
 
sensitivity, but may relate to other signaling
pathways. Consistent with this, targeted disrup-
tion of Stat 6 or Stat 4, transcription factors
downstream of IL-4 and IL-12 signaling, re-
spectively, also can limit mortality of SOCS-1–
deficient mice in the neonatal period (19, 20).
As might be predicted, the aforementioned
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findings implicate dysregulated cytokine signaling as the basis
for the severe pathology that is associated with SOCS-1 defi-
ciency. However, there is limited understanding of the
mechanisms that drive production of these cytokines.
The role of T lymphocytes in the disease that is associated
with SOCS-1 deficiency is unclear. Crossing SOCS-1–defi-
cient mice to RAG-2–deficient mice, which do not make
lymphocytes, reduces serum levels of IFN-
 
 
 
 and prevents
neonatal mortality (17); this suggests that lymphocytes have a
role in IFN-
 
 
 
 production and are essential for disease. Re-
constitution of RAG-2
 
 
 
/
 
 
 
 mice (WT for SOCS-1) with
SOCS-1
 
 
 
/
 
 
 
 hematopoietic progenitors resulted in death
within 7 wk (19), which indicated that deficiency of SOCS-1
in bone marrow–derived cells is sufficient to cause disease. To
examine specifically whether lack of expression of SOCS-1 in
T cells can lead to pathology, Chong et al. (13) engineered
targeted disruption of SOCS-1 in T cells. This led to typical
phenotypic changes in T cells that are associated with SOCS-1
deficiency, but mice showed no overt signs of disease and
were protected from neonatal mortality. This indicated that
SOCS-1 deficiency within T cells alone was insufficient to
cause pathology of SOCS-1–deficient mice.
Although Chong et al. (13) did not observe disease when T
cells alone lacked SOCS-1, expression of this molecule within
T cells was important for the normal homeostasis of this popula-
tion (13, 21). Mice with SOCS-1–deficient T cells showed an
enhanced ratio of mature CD8/CD4 cells in the thymus, and
an increase in the number and proportion of memory pheno-
type CD44
 
hi
 
CD8 T cells in the periphery. The increase in
CD44
 
hi
 
CD8 T cells did not depend on recognition of foreign
ligand, because a similar increase was seen when SOCS-1–defi-
cient mice were crossed to transgenic OT-I mice that express a
class I–restricted OVA-specific TCR (21). This even was true
when these mice were crossed additionally to a RAG-1
 
 
 
/
 
 
 
background to prevent endogenous receptor rearrangement.
Although the phenotypic T cell changes did not seem to de-
pend on foreign antigen, and SOCS-1 deficiency in T cells
alone failed to precipitate overt pathology, the disease pheno-
type that is associated with SOCS-1 deficiency showed depen-
dence on TCR specificity. Survival of SOCS-1
 
 
 
/
 
 
 
 mice was
extended greatly by introduction of the OVA-specific TCR
transgene; survival increased from 12 d for SOCS-1
 
 
 
/
 
 
 
 mice to
75 d for SOCS-1
 
 
 
/
 
 
 
RAG-1
 
 
 
/
 
 
 
 mice expressing the OT-I
TCR. Because SOCS-1
 
 
 
/
 
 
 
RAG-1
 
 
 
/
 
 
 
 mice that lacked T cells
survived indefinitely, but similar mice that expressed the OT-I
TCR died within a mean of 75 d, TCR-expressing cells were
implicated in the slow-onset disease progression. Together, the
aforementioned studies supported the conclusions that (a) T
cells were necessary for disease in SOCS-1
 
 
 
/
 
 
 
 mice, (b) their
TCR specificity affected the rate of disease onset, and (c)
SOCS-1 deficiency within non-T cells was essential.
Demonstration that SOCS-1
 
 
 
/
 
 
 
 mice that were manipu-
lated additionally to transgenically express SOCS-1 only in B
and T lymphocytes, survived for 
 
 
 
6 mo (compared with
only 3 wk for unmanipulated SOCS-1
 
 
 
/
 
 
 
 mice [22]), sug-
gests that SOCS-1 deficiency in T cells is central to severe
disease onset. Although the slower onset of disease in OT-I.
SOCS-1
 
 
 
/
 
 
 
RAG-1
 
 
 
/
 
 
 
 mice, compared with SOCS-1
 
 
 
/
 
 
 
mice, suggests that TCR specificity contributes to severity, it
is unclear whether any level of specificity is required for slow
disease progression. Clearly, the antigenic ligand OVA is not
expressed in OT-I.SOCS-1
 
 
 
/
 
 
 
RAG-1
 
 
 
/
 
 
 
 mice, but speci-
ficity for self-ligands associated with, for example, homeo-
static proliferation (23–25) may contribute.
To understand the basis of the T cell phenotype in SOCS-
1–deficient mice, their responsiveness to cytokines that signal
through the common 
 
 
 
 chain receptor subunit was examined
(10, 11). IL-2 and -15, but not IL-7, induced proliferation of
SOCS-1
 
 
 
/
 
 
 
 
 
CD8
 
 
 
 T cells in vitro. In particular, CD44
 
hi
 
CD8
T cells showed a fivefold greater sensitivity to these cytokines
when compared with WT cells. This same population dem-
onstrated an increased capacity for bystander proliferation in
response to polyinosine-polycytidylic acid
 
 
 
(poly I:C) adminis-
tration in vivo, and proliferated more vigorously when trans-
ferred into T cell–depleted recipients—referred to as homeo-
static proliferation. This led to the conclusion that the
peripheral phenotype of SOCS-1–deficient CD8 T cells re-
lated to an increased sensitivity of memory CD8 T cells to IL-
15 receptor signaling (11). However, because naive T cells
adopt a memory phenotype after they are induced to prolifer-
ate homeostatically, these studies failed to exclude IL-15–
driven expansion of naive CD8 T cells. Consistent with this
possibility, studies using TCR transgenic SOCS-1–deficient
mice showed TCR signaling by foreign antigen was not re-
quired for up-regulation of CD44 (21).
The aforementioned studies suggest that T cells are vital
for disease in SOCS-1
 
 
 
/
 
 
 
 mice, that their specificity is impor-
tant, and that the phenotypic changes to this population may
be related to increased sensitivity to cytokines that signal
through the common 
 
 
 
 chain receptor subunit. Our studies
aimed to determine (a) the precise cytokine(s) that is responsi-
ble for phenotypic changes in vivo, (b) whether antigen-naive
T cells could be affected, (c) the basis for TCR specificity re-
quirements, and (d) whether SOCS-1 deficiency in T cells
could affect their autoimmune potential. Here, we show that
SOCS-1–deficient CD8, but not CD4, T cells proliferate
when transferred into normal T cell–sufficient mice; that this
is related to their specificity for self-ligands (that normally
drive homeostatic proliferation in T cell-deficient mice); and
that it is mediated by IL-15 hypersensitivity in vivo. Finally,
we provide compelling evidence that the CD8 T cell reper-
toire of SOCS-1–deficient mice contains a greater proportion
of autoreactive T cells and that, as a population, these cells
have an increased autoimmune potential.
 
RESULTS
Dissecting the T cell phenotype of SOCS-1–deficient mice
 
To determine whether the phenotypic changes to CD8 T
cells in SOCS-1
 
 
 
/
 
 
 
 mice were due to their SOCS-1–defi-
cient environment or an innate property of the cells them- 
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selves, we examined the fate of SOCS-1
 
 
 
/
 
 
 
 T cells after
adoptive transfer into normal C57BL/6 (B6) hosts. To ob-
tain sufficient T cells, it was necessary to cross the SOCS-1
 
 
 
/
 
 
 
mice to IFN-
 
 
 
 
 
/
 
 
 
 mice, which do not suffer neonatal lethal-
ity (15–17). SOCS-1
 
 
 
/
 
 
 
IFN-
 
 
 
 
 
/
 
 
 
 T cells were labeled with
carboxy fluorescein diacetate succinimidyl ester (CFSE) and
then transferred into B6 mice (containing a full complement
of T cells). 6 d later, spleen cells were recovered, stained for
CD4 and CD8, and analyzed by flow cytometry. As shown
in Fig. 1, CD8, but not CD4, T cells from SOCS-1
 
 
 
/
 
 
 
IFN-
 
 
 
 
 
/
 
 
 
 mice proliferated upon adoptive transfer into normal
mice, whereas no such proliferation was seen when SOCS-
1–expressing T cells were transferred. Although previous
studies had observed enhanced proliferation of SOCS-1
 
 
 
/
 
 
 
CD8 T cells when adoptively transferred into T cell–defi-
cient mice or when examined in intact SOCS-1
 
 
 
/
 
 
 
 mice
given poly I:C (or untreated), our data provided the first ev-
idence that SOCS-1
 
 
 
/
 
 
 
CD8 T cells, but not CD4 T cells,
proliferated in a normal T cell–sufficient environment.
Although the proliferation that was seen for SOCS-1
 
 
 
/
 
 
 
CD8 T cells likely was cytokine driven, it was unclear
whether there also were TCR signaling requirements. If so,
these could have related to several forms of antigenic stimula-
tion, including heightened responses to microbial or food an-
tigens, inappropriate responses to self-antigens, or responses
induced by low-level TCR signaling that was not associated
with antigenic ligation. To distinguish between some of these
possibilities, we examined the influence of TCR specificity on
this response by crossing the SOCS-1
 
 
 
/
 
 
 
 mice to OT-I trans-
genic mice that express a class I–restricted OVA-specific
TCR. These mice, like the SOCS-1
 
 
 
/
 
 
 
 mice, died at a rela-
tively young age (21); to avoid this problem we made irradi-
ated bone marrow chimeric mice by transfer of bone marrow
from young OT-I.SOCS-1
 
 
 
/
 
 
 
 mice into irradiated B6 recipi-
ents. Such OT-I.SOCS-1
 
 
 
/
 
 
 
→
 
B6 chimeric mice survived for
 
 
 
1 yr (unpublished data). To exclude further the influence of
endogenously rearranged TCRs, OT-I.SOCS-1.RAG-1
 
 
 
/
 
 
 
mice were generated. Unless otherwise stated, OT-I.SOCS-1
T cells were obtained from the spleen and/or lymph nodes of
OT-I.SOCS-1.RAG-1
 
 
 
/
 
 
 
→
 
B6 mice for all subsequent ex-
periments. When OT-I.SOCS-1
 
 
 
/
 
 
 
RAG-1
 
 
 
/
 
 
 
 CD8 T cells
from these chimeras were transferred into WT B6 mice con-
taining a full repertoire of T cells (Fig. 2), these cells prolifer-
ated similarly to CD8 T cells from the SOCS-1
 
 
 
/
 
 
 
IFN-
 
 
 
 
 
/
 
 
 
mice (Fig. 1). The ability of OVA-specific SOCS-1
 
 
 
/
 
 
 
 CD8
T cells to proliferate in normal mice in the absence of their
specific antigen, OVA, indicated that stimulation by foreign
antigen was not necessary for SOCS-1–deficient CD8 T cells
to proliferate when transferred into normal mice.
We reported previously that SOCS-1
 
 
 
/
 
 
 
RAG-1
 
 
 
/
 
 
 
mice, which do not contain T cells, survive and are healthy
in a germ-free environment. In contrast, SOCS-1
 
 
 
/
 
 
 
RAG-
1
 
 
 
/
 
 
 
OT-I mice, which only possess OVA-specific CD8 T
cells, have a mean survival time of 72 d (21). This indicates
that T cells are essential for disease, and suggests that under-
standing the basis of dysregulated activation and proliferation
of these cells in OT-I.SOCS-1
 
 
 
/
 
 
 
 mice is important.
It has been shown that TCR specificity can determine
whether T cells proliferate homeostatically when adoptively
transferred into T cell–deficient mice (23–25). An example
of this is the ability of OVA-specific OT-I CD8 T cells (23),
but not H-Y–specific transgenic CD8 T cells (26), to un-
dergo homeostatic proliferation when transferred into suble-
thally irradiated (T cell–depleted) B6 hosts (Fig. 3 A). In this
case, H-Y–specific T cells do not seem to receive sufficient
TCR signaling from endogenous self-antigens to induce ho-
meostatic proliferation, whereas OT-I T cells are stimulated
Figure 1. CD8  SOCS-1–deficient T cells proliferate in C57BL/6 
mice. SOCS-1.IFN-  /  T cells were labeled with CFSE and adoptively 
transferred into C57BL/6 mice. 6 d later, splenocytes were stained for CD4 
and CD8 and analyzed by flow cytometry. Histograms are gated for CD4  
or CD8  cells; the percentages shown are the proportion of cells that have 
reduced CFSE intensity.
Figure 2. OT-I.SOCS-1–deficient CD8 T cells proliferate in C57BL/6 
mice. OT-I.SOCS-1.RAG-1 /  T cells from bone marrow chimeras were 
labeled with CFSE and adoptively transferred into C57BL/6 mice. 6 d later, 
lymph node cells were stained for CD8 and analyzed by flow cytometry. 
Histograms are gated for CD8  cells; the percentages shown are the 
proportion of cells that have reduced CFSE intensity.SOCS-1, IL-15, AND AUTOIMMUNITY | Davey et al. 1102
sufficiently. To determine whether such TCR specificity
also affected proliferation of SOCS-1 /  CD8 T cells that
were transferred into T cell–sufficient mice, we examined
proliferation of OT-I and H-Y T cells from their respective
SOCS-1 /  crosses after transfer into normal B6 mice (Fig.
3 B). The ability of OT-I.SOCS-1 / , but not H-Y.SOCS-
1 / , CD8 T cells to proliferate indicated that proliferation
depended on TCR specificity.
One caveat to the aforementioned conclusion is that
memory CD8 T cells are generally less reliant on MHC I
recognition for homeostatic proliferation than are naive T
cells (27, 28). Because most OT-I.SOCS-1 /  cells have a
memory phenotype, whereas most HY.SOCS-1 /  cells are
naive (see next paragraph), it remained possible that differ-
ences in proliferation might relate to their state of activation.
To assess further the requirement for a TCR signal in the
initiation of OT-I.SOCS-1 /  T cell proliferation,
OT-I.SOCS-1 / IFN-  /  CD8 CD4  thymocytes were
adoptively transferred into B6 or TAP1 /  T cell–sufficient
hosts, the latter of which express only very low levels of
MHC class I. In this case, we used thymocytes as the source
of naive, mature CD8 T cells because OT-I.SOCS-1 / 
mice have few CD44low cells in their periphery. Analysis of
proliferation on day 7 after transfer (Fig. 3 C) showed that
naive OT-I.SOCS-1 / IFN-  /  CD8 T cells failed to
proliferate in a TAP1 /  host, but proliferated efficiently in
B6 mice. This demonstrated clearly a requirement for MHC
class I recognition for proliferation.
Figure 3. H-Y.SOCS-1–deficient CD8 T cells do not proliferate in 
C57BL/6 mice. OT-I.SOCS-1.RAG-1 /  or H-Y.SOCS-1.RAG-1 /  T cells 
from bone marrow chimeras were labeled with CFSE and adoptively trans-
ferred into C57BL/6 recipients. SOCS-1 /  cells were transferred into irra-
diated (700 cGy) C57BL/6 mice (A) and SOCS-1 /  cells were transferred 
into unmanipulated C57BL/6 mice (B). 5 or 6 d later, splenocytes were 
stained for CD4 and CD8 and analyzed by flow cytometry. Histograms are 
gated for CD8  cells; the percentages shown are the proportion of cells 
that have reduced CFSE intensity. (C) SOCS-1 /  OT-I T cells do not prolif-
erate in TAP1 /  mice. Thymocytes from OT-I.SOCS-1 / .IFN-  /  mice 
were enriched for CD8 CD4  cells, labeled with CFSE, and transferred into 
C57BL/6 or TAP1 /  recipients. Recipient TAP1 /  mice had been treated 
15 d earlier with a single i.p. injection of anti-CD8 mAb to remove residual 
CD8 T cells. 7 d later, splenocytes were labeled with CD8-specific mAb and 
analyzed by flow cytometry. Line graphs are gated for CD8  cells; the 
percentages shown are the proportion of cells that have reduced CFSE 
intensity. Results from a single experiment, two mice per group.
Figure 4. CD44 expression is up-regulated on SOCS-1–deficient 
CD8 T cells from C57BL/6 or OT-I, but not H-Y mice. (A) CD44 ex-
pression of CD8  splenocytes from SOCS-1 /  (left) and SOCS-1 /  (right) 
SOCS-1.IFN-  /  mice (i), OT-I.SOCS-1.RAG-1 / →B6 chimeras (ii), and 
H-Y.SOCS-1.RAG-1 / →B6 chimeras (iii). (B) SOCS-1 / .IFN-  /  CD8 
T cells were sorted into CD44lo and CD44high populations, labeled with CFSE, 
and transferred into C57BL/6 recipients. 6 d later splenocytes, were labeled 
with CD8 and CD44 and analyzed by flow cytometry. Histograms are gated 
for CD8  cells from mice that received CD44low cells (left) or CD44high cells 
(right). The percentages shown are the proportion of cells that have reduced 
CFSE intensity.JEM VOL. 202, October 17, 2005 1103
ARTICLE
In accordance with the aforementioned finding, like
SOCS-1 /  mice, OT-I.SOCS-1 /  mice, but not H-Y.
SOCS-1 /  mice, showed an increase in the proportion
of CD44hiCD8 T cells (Fig. 4 A). Thus, the increase in
CD44hi memory–phenotype CD8 T cells in SOCS-1 / 
mice is not an innate property of all CD8 T cells, but de-
pends upon TCR specificity. Only naive CD8 T cells with
an appropriate “self”-specificity are able to be transformed
into CD44hi cells. The failure of SOCS-1–deficient H-Y,
but not OT-I, cells to proliferate and up-regulate CD44 ex-
cluded the possibility that responses were induced by low-
level TCR signaling in the absence of antigenic ligation.
Further evidence that supported the idea that SOCS-1
deficiency may allow only a proportion of CD8 T cells to
proliferate and up-regulate CD44 was shown by sorting a
normal repertoire of SOCS-1–deficient CD8 T cells into
CD44high and CD44low before adoptive transfer into WT
mice. Only the CD44high cells proliferated upon transfer into
T cell–sufficient B6 hosts (Fig. 4 B). This indicates that a
proportion of CD8 T cells, like the H-Y T cells, never up-
regulate CD44 and do not proliferate, even though they are
SOCS-1 deficient.
Because the TCR specificity for proliferation of SOCS-
1 /  T cells in T cell–sufficient mice paralleled that for ho-
meostatic proliferation of normal T cells in T cell–deficient
mice, we considered it likely that the T cell phenotype in
SOCS-1 /  mice related to their enhanced sensitivity to ho-
meostatic proliferation signals. For CD8 T cells, IL-7 and -15
were reported to control homeostatic proliferation when T
cells were depleted. Naive CD8 cells are highly dependent on
IL-7, although they also can respond to IL-15. In contrast,
memory CD8 T cells respond mainly to IL-15, with a re-
duced responsiveness to IL-7 (28, 29). To examine the depen-
dence of OT-I.SOCS-1 /  CD8 T cells on these two cyto-
kines, we adoptively transferred OT-I.SOCS-1 /  cells into
mice that were deficient for either of these cytokines. As
shown in Fig. 5 A, these cells proliferated in control B6 mice
and in IL-7 /  mice, but failed to divide in IL-15 /  mice.
This provided the first direct evidence that IL-15 was respon-
sible for driving proliferation in vivo. To confirm the depen-
dence of SOCS-1 /  CD8 T cells on IL-15 for proliferation,
purified T cells from SOCS-1 / IFN-  /  mice were labeled
with CFSE and adoptively transferred into B6 or IL-15 / 
mice. 6 d later, cells were recovered, stained for CD8, and
examined for proliferation by flow cytometry (Fig. 5 B). Con-
sistent with our findings with OT-I.SOCS-1 /  cells, SOCS-
1 / IFN-  /  CD8 T cells from a normal repertoire did not
proliferate in IL-15 /  mice, but proliferated well in B6 mice.
Having shown that IL-15 was required to drive the pro-
liferation of CD44high SOCS-1–deficient CD8 T cells in
vivo, we were interested in determining whether IL-15 was
expanding an existing population of CD44high CD8 T cells
or, in fact, contributed to the proliferation of naive CD44low
CD8 T cells, which then up-regulated CD44. Because only
low numbers of naive OT-I.SOCS-1 /  cells can be found
in the periphery of OT-I.SOCS-1 /  chimeric mice (Fig. 4
A), thymocytes were sorted for CD44lowCD4 CD8  OT-I.
SOCS-1 cells. As shown in Fig. 5 C, naive CD44low CD8
T cells proliferated in B6 mice, but not in IL-15 /  mice.
This supports the studies in TAP1 /  mice, which suggest
that naive phenotype cells are driven directly to proliferate.
Cells that were transferred into IL-15 /  mice did not up-
regulate CD44 by day 7 (unpublished data), which supports
the view that activation was IL-15 dependent.
These findings are consistent with SOCS-1 deficiency
causing enhanced sensitivity to IL-2  receptor signaling
(11). Our findings show that this leads to increased respon-
siveness to IL-15 in vivo, which causes activation and pro-
liferation of the naive CD8 T cells that express TCR
specificities that normally are associated with homeostatic
proliferation in T cell–deficient environments where IL-7
and IL-15 concentrations are much greater. Once proliferat-
ing, these naive CD8 T cells adopt the CD44high memory
phenotype, but are not—as previously believed—bona fide
memory T cells (11).
Figure 5. SOCS-1 /  CD8 T cells do not proliferate in IL-15 /  
mice. (A) T cells from OT-I.SOCS-1 / .RAG-1 / →B6 mice were labeled 
with CFSE and adoptively transferred into C57BL/6, IL7 /  or IL-15 /  mice. 
7 d later, splenocytes were stained for CD8, V 2, and V 5 and analyzed by 
flow cytometry. Histograms are gated for CD8 V 2 V 5  cells, and the 
percentages shown are the proportion of cells that have reduced CFSE 
intensity. (B) SOCS-1 / .IFN-  /  T cells were labeled with CFSE and adop-
tively transferred into C57BL/6 or IL15 /  mice. 6 d later, splenocytes were 
stained for CD8 and analyzed by flow cytometry. Histograms are gated for 
CD8  cells; the percentages shown are the proportion of cells that have 
reduced CFSE intensity. (C) Thymocytes from OT-I.SOCS-1 / .RAG-1 / →B6 
mice were sorted for CD44low CD8 CD4  cells, labeled with CFSE, and 
transferred into C57BL/6 or IL-15 /  recipients. 7 d later, splenocytes were 
labeled with antibodies for CD8 and analyzed by flow cytometry. Histo-
grams are gated for CD8  cells; the percentages shown are the proportion 
of cells that have reduced CFSE intensity.SOCS-1, IL-15, AND AUTOIMMUNITY | Davey et al. 1104
SOCS-1–deficient autoreactive CD8 T cells are not deleted 
by cross-tolerance
We reported previously that CD8 T cells can be tolerized to
self-antigens that are expressed in extrathymic tissues by a
mechanism that is called cross-tolerance (30). This requires
cross-presentation of tissue antigens on a subset of CD8  
dendritic cells that cause bim-dependent deletion of autore-
active CD8 T cells (31–34). Because SOCS-1 deficiency
causes a proportion of CD8 T cells to proliferate and in-
crease in number, we questioned whether this might pre-
vent cross-tolerance, and therefore, contribute to the auto-
immune phenotype of SOCS-1 /  mice. To determine
whether deletion by cross-tolerance was affected by a
SOCS-1 deficiency in CD8 T cells, we injected WT B6
mice or those expressing soluble OVA in the pancreas (RIP-
OVAhi mice) (35) with SOCS-1–deficient OT-I cells. 1 d
after transfer of the cells, equivalent numbers of OT-I or
OT-I.SOCS-1 /  cells were present in recipient mice
showing a similar “take” of transferred cells (Fig. 6 A). How-
ever, by 6 wk after transfer, normal OT-I cells were deleted
in RIP-OVAhi mice, but survived in nontransgenic control
mice that did not express OVA. Although expression of
OVA in the islets reduced the total number of SOCS-1–
deficient OT-I cells compared with that seen in nontrans-
genic mice, the number of these cells increased compared
with that seen for WT OT-I cells in nontransgenic mice
(Fig. 6 B). Thus, although the cross-tolerance mechanism
reduced the total number of SOCS-1–deficient OT-I cells
that would have accumulated, it was not efficient enough to
reduce this number to less than that originally transferred. In
fact, the total number of OT-I cells increased by approxi-
mately threefold. These findings indicate that the SOCS-1
deficiency in T cells does not inhibit the bim-dependent de-
letion mechanism that is associated with cross-tolerance;
however, the high rate of proliferation that is associated with
lack of SOCS-1 offset the rate of deletion by cross-tolerance.
This leads to an overall failure to reduce autoreactive T cell
numbers to less than their initial value.
SOCS-1–deficient autoreactive CD8 T cells have greater 
autoimmune potential
To determine whether SOCS-1 deficiency might enhance
the ability of T cells to cause autoimmunity, we examined
the induction of diabetes in the RIP-mOVA model (36).
RIP-mOVA mice express a membrane-bound form of
OVA in the islet   cells of the pancreas, and ectopically in
the kidney. Previous studies showed that transfer of 5   106
naive OT-I cells usually causes diabetes in these mice; how-
ever, transfer of  2.5   105 OT-I cells never causes disease
(37). This is in contrast to the RIP-OVAhi mice that were
used for the deletion studies, where only activated OT-I
cells, but not naive cells, are able to cause diabetes following
adoptive transfer. Functional differences between these RIP-
OVA lines probably relates to variations in the amount, na-
ture, and site of antigen expression. To examine autoim-
mune potential, high and low doses of SOCS-1 / .OT-I T
cells were transferred into RIP-mOVA mice. As shown in
Figure 6. SOCS-1–deficient OT-I CD8 T cells are not deleted by 
cross-tolerance. 5   106 OT-I.SOCS-1.RAG-1 / →B6 cells were adop-
tively transferred into RIP-OVAhi or C57BL/6 (nontg) mice. After 1 d (A) or 
6 wk (B), the number of OT-I cells in the lymph nodes and spleen was 
determined. Open circles represent individual mice; the bar and number 
corresponds to the average number of OT-I cells per group. These results 
are pooled data from two to three independent experiments.
Figure 7. SOCS-1–deficient OT-I CD8 T cells have greater 
autoimmune potential. 5   106 (solid lines) or 0.1   106 (dashed lines) 
T cells from OT-I.SOCS-1 / , /  (thin lines) or OT-I.SOCS-1 /  (bold lines) bone 
marrow chimeric mice were adoptively transferred to RIP-mOVA mice. Mice 
were monitored for diabetes by urine glucose for 100 d (15–17 mice/group).JEM VOL. 202, October 17, 2005 1105
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Fig. 7, 0.1   106 OT-I.SOCS-1 /  cells caused diabetes
when adoptively transferred into RIP-mOVA mice, whereas
SOCS WT OT-I cells failed to do so. This provides the first
direct evidence that SOCS-1 deficiency can enhance the ca-
pacity of CD8 T cells to cause autoimmunity, even in recip-
ient mice that are WT for SOCS-1 expression.
DISCUSSION
This study aimed to define better the effects of SOCS-1
within T cells. It had been reported that the major pheno-
typic change in T cells from SOCS-1 /  mice was an in-
crease in the proportion and number of CD44high CD8 T
cells (13, 21). Our studies provide an explanation for this
phenotype. Homeostatic proliferation of naive CD8 T cells
is controlled largely by IL-7 (38, 39), although they can re-
spond weakly to IL-15 (40). Conversely, memory CD8 T
cells respond predominantly to IL-15, and respond poorly to
IL-7 (28, 29). Our data indicate that SOCS-1–deficient
CD8 T cells, which were hyperresponsive in vitro to several
cytokines, including IL-2, -4, and -15 (10, 11), require IL-
15 in vivo to induce CD44 up-regulation and uncontrolled
proliferation (Fig. 5). The uncontrolled proliferation of
CD44high CD8 T cells explains the increased number of
these cells in SOCS-1 /  mice.
Generation of the CD44high phenotype of CD8 T cells
was shown to be highly dependent on their TCR specificity;
SOCS-1 /  HY CD8 T cells showed no up-regulation of
CD44 and no capacity to proliferate upon adoptive transfer
into unmanipulated B6 mice. This contrasts with SOCS-1 / 
OT-I cells, which were largely CD44high and proliferated
extensively upon transfer into normal hosts. The dependence
on TCR signaling for initiation of this proliferation was
shown by the failure of naive SOCS-1 /  OT-I cells from
the thymus to proliferate in mice that were deficient in TAP.
A similar division of T cells in the normal repertoire into
those that proliferate and are CD44high, and those that do not
proliferate and are CD44low, was implicated by comparing
the capacity of CD44high and CD44low SOCS-1 / IFN-  / 
cells to proliferate upon transfer into normal hosts. CD44low
cells largely remained CD44low and did not proliferate,
whereas CD44high cells remained CD44high (not depicted) and
proliferated vigorously (Fig. 4 B). There are two possible ex-
planations for how naive SOCS-1 /  CD8 T cells initially
up-regulate CD44. They have increased sensitivity to IL-15
and this, together with a homeostatic TCR/self-ligand signal,
stimulates this effect. Alternatively, this latter TCR interac-
tion, together with increased IL-7 sensitivity, drives naive
CD8 T cells into memory phenotype cells that lose their sen-
sitivity to IL-7 and gain hypersensitivity to IL-15. Although
there is some evidence that SOCS-1 /  CD4 CD8  thy-
mocytes may have increased sensitivity to IL-7 (13), we favor
the view that naive CD8 T cells are driven by IL-15 hyper-
sensitivity for the following reasons. First, exposure of
SOCS-1 /  T cells to cytokines in vitro shows proliferation
and increased sensitivity to IL-2, -4, and -15, but not IL-7
(10, 11); second, our data, with the transfer of mature naive
CD8 CD4  SOCS-1 /  OT-I thymocytes into IL-7 /  or
IL-15 /  mice showed efficient proliferation in the absence
of IL-7 (not depicted), but not IL-15 (Fig. 5 C). However, a
caveat to the experiments with IL-7 /  hosts is that these
mice are lymphopenic, which may alter the cytokine envi-
ronment and mask an IL-7 dependency. In a preliminary
experiment, we found that OT-I.SOCS-1 /  cells did not
proliferate in IL-7 / IL-15 /  (lymphopenic) mice (unpub-
lished data), which suggests that alternative cytokines could
not substitute for IL-15. However, thus far, it has not been
possible to assess the role of IL-7 in driving SOCS-1 /  T
cell proliferation in a T cell–sufficient environment. Thus,
our studies are consistent with the simplest model where
SOCS-1 /  CD8 T cells are hypersensitive to IL-15, and
this, together with TCR signaling by self-ligands, drives their
proliferation and conversion to memory phenotype cells.
In addition to providing an explanation for the pheno-
type of SOCS-1 /  T cells, it was important to address their
autoimmune potential and susceptibility to tolerance induc-
tion. By using well-defined models of peripheral cross-toler-
ance induction (31–35), we were able to show that SOCS-
1 /  CD8 T cells are deleted inefficiently by cross-tolerance.
This mechanism relies on the presentation of tissue-derived
OVA by a subset of CD8   dendritic cells (34) that stimu-
late proliferation, and ultimately, the deletion of OVA-spe-
cific “self-reactive” CD8 T cells (31, 32). When such CD8
T cells were SOCS-1 deficient they were not deleted from
the repertoire (Fig. 6), although when compared with simi-
lar cells that were transferred into mice that did not express
OVA, their numbers were reduced. This suggests that
SOCS-1 does not block cross-tolerance–mediated deletion
specifically, but simply that the rate of deletion by cross-tol-
erance is slower than the rate of expansion that is driven by
the IL-15 hypersensitivity of SOCS-1–deficient cells. The
consequence of this imbalance is that SOCS-1 /  mice
slowly accumulate, rather than delete, CD8 T cells with au-
toreactivity. These studies predict that within the normal
repertoire of a SOCS-1 /  mouse there will be more surviv-
ing autoreactive T cells than in WT mice. Just how many
more is not predictable because there is no means to measure
the contribution of cross-tolerance to the control of a nor-
mal peripheral T cell repertoire.
In addition to showing that autoreactive T cells may ac-
cumulate, we were able to examine the consequence of their
presence. The ability of 105 SOCS-1 / , but not WT OT-I,
cells to cause autoimmune diabetes in RIP-mOVA mice in-
dicated that as a population, these cells are more autoaggres-
sive than are their WT counterparts. In other words, there is
no reason to invoke increased autoaggression on a per cell
basis (though this is not excluded), because autoimmunity
may be potentiated simply by an ever increasing number of
autoreactive cells, which are unable to be deleted. These
findings contradict the studies of Chong et al. (13), who
found no signs of autoimmunity in mice bearing SOCS-1SOCS-1, IL-15, AND AUTOIMMUNITY | Davey et al. 1106
deficiency only in T cells. However, two important points
need to be considered. First, although our data indicate that
self-reactive T cells may accumulate and that, as a popula-
tion, these cells may cause autoimmunity, we cannot deter-
mine how many such cells accumulate for a normal TCR
repertoire. Perhaps this number is rather low and the result-
ant increase in autoaggression is insufficient to cause disease
when SOCS-1 is only deficient within the T cells. Second,
with respect to this last point, in a mouse where SOCS-1 is
deficient in all tissues, the combination of innate immune
cells (such as macrophages and NK cells) and the tissues
themselves being hypersensitive to cytokine signaling, to-
gether with the increased autoaggression of the undeleted
autoreactive CD8 T cell population, might be sufficient to
trigger overt autoimmunity. Future experiments will assess
the increase in autoimmune potential when other bone mar-
row–derived cells or the islet   cells themselves also are defi-
cient in SOCS-1.
In addition to the aforementioned contributions to SOCS-
1 /  autoimmunity, these findings raise the possibility that an-
other set of autoreactive T cells may participate in disease.
There is evidence that some self-reactive cells ignore their au-
toantigen, and remain as sessile naive cells in the periphery of
normal animals (31, 41, 42). Such cells have autoimmune po-
tential if activated by cross-reactive environmental ligands.
However, if cells of this type could receive homeostatic TCR
signals when SOCS-1 deficient, they may become autoaggres-
sive. Future studies will examine this possibility.
In summary, our studies provide an explanation for T
cell–dependent destructive autoimmune disease that is seen
in SOCS-1 /  mice. SOCS-1 /  naive CD8 T cells are
triggered by self-ligands and hypersensitivity to IL-15 to up-
regulate CD44 and proliferate. These cells are poorly suscep-
tible to peripheral tolerance induction, and in combination
with the increased cytokine sensitivity of target tissues, have
strong potential to cause autoimmunity.
MATERIALS AND METHODS
Mice.  All mice were bred and maintained at the Walter and Eliza Hall In-
stitute for Medical Research, except for the IL-7– and IL-15–deficient
mouse lines that were maintained at The Scripps Research Institute. Trans-
genic, OT-I (43), RIP-mOVA (36), RIP-OVAhi (35), and H-Y (44) mice
and knockout SOCS-1 (12), SOCS-1.IFN-  /  (15), RAG-1 (45), IL-15
(46), IL-7 (47), and TAP1 (48) mice have been described previously. All
studies were performed according to protocols approved by the Melbourne
Health Animal Ethics Committee.
Bone marrow chimeras. OT-I.SOCS-1→B6 or OT-I.SOCS-1.RAG-
1 / →B6 bone marrow chimeras were generated as follows. Adult C57BL/6
mice were irradiated lethally with two doses of 550 cGy 3 h apart, and were
reconstituted with 5   106 T cell–depleted OT-I.SOCS-1 bone marrow
cells. T cell depletion was performed by incubating with anti-CD4
(RL172), anti-CD8 (3.168), and anti-Thy1 (J1j) mAbs and treatment with
rabbit complement. On day 1 after reconstitution, all mice were injected
i.p. with 100  g anti-Thy1 mAb (T24) to eliminate radioresistant host T
cells. The mice were left for 8–10 wk before use.
Female H-Y.SOCS-1 / .RAG-1 /  mice were moribund at 2–3 wk
of age, before bones were processed easily for bone marrow harvesting.
Therefore, H-Y.SOCS-1→B6 chimeras were prepared using whole spleen
cells from 2–3-wk-old H-Y.SOCS-1 neonates. This approach was not nec-
essary for OT-I-SOCS-1 / RAG-1 /  mice, which live for 3–6 wk and
can provide sufficient bone marrow for chimera generation.
Carboxy fluorescein diacetate succinimidyl ester labeling adoptive
transfer and FACS analysis.  CD8 T cells, from lymph nodes and
spleen, were enriched by incubation with anti-CD4 (RL172) and anti-HSA
(J11d) mAb followed by rabbit complement. For carboxy fluorescein diace-
tate succinimidyl ester (CFSE)-labeling, cells were resuspended at 107 cells/
ml in 0.1% BSA/PBS and incubated with 5  M CFSE stock solution (5 mM
in DMSO; Invitrogen) for 10 min at 37 C. 1–2   106 CFSE-labeled T cells
were injected i.v. into unmanipulated C57BL/6 mice or mice that had been
exposed to 700 cGy whole body irradiation 3–4 h earlier. 5–7 d later, lymph
nodes and/or spleens were harvested and analyzed by flow cytometry on a
FACScan or BD-LSR (Becton Dickinson) instrument. Antibodies used for
flow cytometry staining were CD44, CD4, CD8, V 2-TCR (Caltag Labs;
BD Biosciences) and H-Y-TCR (T1/70) (provided by A. Strasser, Walter
and Eliza Hall Institute of Medical Research, Victoria, Australia).
For the adoptive transfer of sorted CD44 subsets, thymocytes or lymph
node and spleen CD8 T cells were enriched by magnetic bead depletion of
CD4 T cells and B cells using anti-CD4 (GK1.5) and anti-HSA (J11d)
(lymph node and spleen only) antibodies, followed by anti–rat IgG and
anti–mouse IgG magnetic beads (QIAGEN). Subsequent CD44 separation
was achieved using anti-CD44 antibody and either MACS microbeads and
autoMACS columns (Miltenyi Biotec) or MoFlo (DakoCytomation) flow
cytometry sorting. Sorted cell populations were labeled with CFSE before
transfer to recipient mice.
For the adoptive transfer into TAP1 /  mice, the residual CD8 T cells
had to be depleted to prevent rejection of the transferred OT-I cells ex-
pressing high MHC class I levels relative to the TAP1 /  hosts (49). TAP1
and C57BL/6 controls were given a “low-dose” injection of 50  l anti-
CD8 mAb ascites, 15 d before adoptive transfer of OT-I.SOCS-1.IFN-  / 
thymocytes. Mice were bled on the day of transfer to determine the re-
maining CD8 T cell population.
Cross-tolerance deletion experiments. 5   106 OT-I.SOCS-1→B6 T
cells were enriched for CD8 T cells, by antibody and complement deple-
tion, and injected i.v. into recipient mice. After 1 d or 6 weeks, spleen and
lymph nodes were removed and assessed for the number of OT-I T cells
present by staining with anti-TCR antibodies or tetramers. For antibody
staining, anti–V 5-FITC (MR9-40), anti–CD8-Pe (Caltag Labs), and anti–
V 2-biotin (B20.1) revealed with Streptavidin Tricolor (Caltag Labs) were
used. For tetramers, OT-I T cells were revealed by staining with Kb-
OVA257-264 tetramer-PE and anti–CD8-FITC (Caltag Labs). The total
number of OT-I T cells was determined from the formula: (% OT-I in the
CD8  cells of adoptively transferred mice   background)   (% CD8  T
cells in total live cells)   total cell number/10,000. Background was the
percentage TCRV 2  or tetramer  cells in uninjected mice; on average,
this was 1.4% for mAb and 0.1% for tetramer-stained cells. Total cell num-
bers were determined by flow cytometry using a known number of small
nonfluorescent Sphero beads (BD Biosciences) added to a known volume of
the cell sample. Therefore, cells/ml   number cells collected   (numbers
beads in sample/number beads collected)   1/sample volume.
Diabetes. Lymph node T cells from OT-I.SOCS-1→B6 mice, enriched
by antibody and rabbit complement depletion, were adoptively transferred
by i.v. injection into the lateral tail vein of RIP-mOVA mice. Two doses of
cells were used, either 5   106 or 0.1   106 CD8  cells per mouse. Recip-
ient mice were monitored for diabetes, by urine glucose testing, from day 5
after transfer. Animals were monitored for 3 mo and were considered dia-
betic after two consecutive days with readings  55 mmol/L.
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